CO2021014988A2 - Trispecific and/or trivalent binding proteins using the crossover dual domain variable (codv) format for the treatment of hiv infection - Google Patents

Trispecific and/or trivalent binding proteins using the crossover dual domain variable (codv) format for the treatment of hiv infection

Info

Publication number
CO2021014988A2
CO2021014988A2 CONC2021/0014988A CO2021014988A CO2021014988A2 CO 2021014988 A2 CO2021014988 A2 CO 2021014988A2 CO 2021014988 A CO2021014988 A CO 2021014988A CO 2021014988 A2 CO2021014988 A2 CO 2021014988A2
Authority
CO
Colombia
Prior art keywords
binding proteins
trispecific
treatment
codv
format
Prior art date
Application number
CONC2021/0014988A
Other languages
Spanish (es)
Inventor
Jochen Beninga
Ercole Rao
Christian Beil
Zhi-Yong Yang
Joerg Birkenfeld
Gary J Nabel
Ronnie Wei
Ling Xu
Mangaiarkarasi Asokan
Mark Connors
Richard A Koup
Young Do Kwon
Peter D Kwong
Qingbo Liu
Paolo Lusso
John R Mascola
Amarendra Pegu
Original Assignee
Sanofi Sa
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Us Health filed Critical Sanofi Sa
Publication of CO2021014988A2 publication Critical patent/CO2021014988A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

En el presente documento se proporcionan composiciones que comprenden proteínas de unión triespecíficas y/o trivalentes que comprenden cuatro cadenas polipeptídicas que forman tres sitios de unión a antígeno que se unen específicamente a una o más proteínas diana del VIH, en las que un primer par de polipéptidos que forman la proteína de unión poseen dominios variables dobles que tienen una orientación cruzada, y en la que el segundo par de polipéptidos posee un dominio variable único. También se proporcionan en el presente documento métodos para preparar proteínas de unión triespecíficas y/o trivalentes y usos de dichas proteínas de unión para el tratamiento y/o la prevención del VIH/SIDA.Provided herein are compositions comprising trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen-binding sites that specifically bind one or more HIV target proteins, wherein a first pair of polypeptides that form the binding protein have double variable domains that have a cross-over orientation, with the second pair of polypeptides having a single variable domain. Also provided herein are methods for preparing trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/AIDS.

CONC2021/0014988A 2019-04-09 2021-11-05 Trispecific and/or trivalent binding proteins using the crossover dual domain variable (codv) format for the treatment of hiv infection CO2021014988A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831415P 2019-04-09 2019-04-09
EP19306312 2019-10-08
PCT/US2020/027313 WO2020210386A1 (en) 2019-04-09 2020-04-08 Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection

Publications (1)

Publication Number Publication Date
CO2021014988A2 true CO2021014988A2 (en) 2022-01-17

Family

ID=70471109

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0014988A CO2021014988A2 (en) 2019-04-09 2021-11-05 Trispecific and/or trivalent binding proteins using the crossover dual domain variable (codv) format for the treatment of hiv infection

Country Status (13)

Country Link
EP (1) EP3953384A1 (en)
JP (1) JP2022526826A (en)
KR (1) KR20210149796A (en)
CN (1) CN114096561A (en)
AU (1) AU2020273156A1 (en)
CA (1) CA3136147A1 (en)
CO (1) CO2021014988A2 (en)
IL (1) IL286932A (en)
MA (1) MA55609A (en)
MX (1) MX2021012384A (en)
SG (1) SG11202111011SA (en)
TW (1) TW202104274A (en)
WO (1) WO2020210386A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
BR112014010823B1 (en) 2011-11-07 2021-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services antibodies that bind to gp41 and neutralize human immunodeficiency virus type 1 (hiv-1), its uses, nucleic acid molecule, expression vector, composition, kit, as well as methods for detecting hiv-1 infection and potential immunogen test
CN108676091B (en) 2011-12-08 2022-04-01 美国政府(由卫生和人类服务部的部长所代表) Neutralizing antibodies to HIV-1 and uses thereof
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
WO2017011414A1 (en) * 2015-07-10 2017-01-19 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
PE20181167A1 (en) 2015-10-25 2018-07-19 Sanofi Sa TRIESPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR THE PREVENTION OR TREATMENT OF HIV INFECTION
SG11201808911SA (en) 2016-04-13 2018-11-29 Sanofi Sa Trispecific and/or trivalent binding proteins

Also Published As

Publication number Publication date
TW202104274A (en) 2021-02-01
AU2020273156A1 (en) 2021-12-02
KR20210149796A (en) 2021-12-09
MA55609A (en) 2022-02-16
MX2021012384A (en) 2022-02-21
EP3953384A1 (en) 2022-02-16
WO2020210386A1 (en) 2020-10-15
JP2022526826A (en) 2022-05-26
CA3136147A1 (en) 2020-10-15
IL286932A (en) 2021-10-31
CN114096561A (en) 2022-02-25
SG11202111011SA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
CO2018005337A2 (en) Trispecific and / or trivalent binding proteins for the prevention or treatment of HIV infection
PH12018502182A1 (en) Trispecific and/or trivalent binding proteins
CU20180084A7 (en) IMMUNOGLOBULIN WITH FABS IN TANDEM
CO2020016559A2 (en) Antibodies that target hiv gp120 and methods of use
SA517390092B1 (en) Designed Ankyrin Repeat Domains with Binding Specificity for Serum Albumin
CL2020003071A1 (en) Multispecific binding proteins and enhancements with them
PE20170767A1 (en) COVALENTLY LINKED DIACBODIES HAVING IMMUNOREACTIVITY WITH PD-1 AND LAG-3, AND METHODS OF USE OF THE SAME
MY196882A (en) Recombinant binding proteins and their use
CL2019002626A1 (en) Anti-par2 antibodies and their uses.
BR112017011478A2 (en) antibody-antibiotic conjugate compound, antibody-antibiotic conjugate, pharmaceutical composition, methods of treating a bacterial infection and exterminating staph aureus, process for compound preparation, kit and antibiotic-binder intermediate
EA201890914A1 (en) DELIVERY PROTEIN BACTERIA
DOP2017000246A (en) POLIPEPTIDES DIRECTED TO HIV FUSION
BR112016015867A2 (en) high affinity and aggregation resistant antibodies based on variable regions vl and derivative vhh
BR112021025655A2 (en) Human immunodeficiency virus replication inhibitors
MX2023004804A (en) Trispecific and/or trivalent binding proteins.
CO2021014988A2 (en) Trispecific and/or trivalent binding proteins using the crossover dual domain variable (codv) format for the treatment of hiv infection
CY1124244T1 (en) ANTIBODY VARIANTS
AR118602A1 (en) TRIESPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR THE TREATMENT OF HIV INFECTION
ECSP18039758A (en) TRIESPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR THE PREVENTION OR TREATMENT OF HIV INFECTION
EA201992587A1 (en) PEPTIDES AND THEIR APPLICATION AS ANTIVIRAL AGENTS
EA202191078A3 (en) TRISSPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION
CO2021014918A2 (en) Trispecific binding proteins, methods and uses thereof
TR201917122A2 (en) CONJUGATION OF PROTEIN DRUGS WITH BIOPOLYMERS BY ENzymatic route
EA201892788A1 (en) POLYALKYLENOXIDE-ASPARAGINASE PREPARATIONS AND METHODS FOR THEIR PRODUCTION AND USE